Should I buy GSK shares or FTSE 100 rival AstraZeneca?

G A Chester weighs the merits of FTSE 100 (INDEXFTSE:UKX) pharmaceuticals giants GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price is currently 1,560p and the AstraZeneca (LSE: AZN) share price is 5,850p. The companies have market capitalisations of £78bn and £77bn, respectively. They’re the Titans of London-listed pharmaceuticals firms. Indeed, they rank as the fourth and fifth largest stocks in the FTSE 100. But which do I think is the better buy today?

Encouraging start to the year

AstraZeneca released its first-quarter results today. There were some impressive headline numbers. Total revenue rose 11% at constant exchange rates, core operating profit was up 96% on strong margin improvement, and core earnings per share (EPS) increased 100%.

The company described the performance as an “encouraging financial start to the year,” and noted also that “our highly-productive and sustainable pipeline continued to deliver.”

Looking to full-year 2019

Advising that variation in performance between quarters can be expected, AstraZeneca reiterated its previous guidance for full-year 2019 core EPS of between $3.50 and $3.70 (271p-287p at current exchange rates, with 279p at the midpoint). The midpoint EPS would represent an increase of 4% on 2018 earnings, and put the stock on a forward price-to-earnings (P/E) ratio of 21 at the current share price.

Meanwhile, the prospective dividend yield on an anticipated unchanged payout of $2.80 (217p) would be 3.7%.

Rival full-year expectations

GSK will release its first-quarter results next week (Wednesday). As management’s guidance for full-year 2019 currently stands, we can expect a decline in underlying EPS of between 5% and 9% on 2018’s earnings (at constant exchange rates). This would imply EPS of 109p-113p, and at the midpoint 111p would put the stock on a forward P/E of 14 at the current share price.

Meanwhile, the prospective dividend yield on a management-guided unchanged payout of 80p would be 5.1%.

Looking to 2020

In terms of P/E, GSK (14) appears to offer considerably better value than AstraZeneca (21). Its dividend yield is also much superior: 5.1% versus 3.7%.

Looking ahead to 2020 forecast earnings, modest growth for GSK lowers its P/E to 13.5. And while the City consensus is for much stronger growth at AstraZeneca, the P/E remains comparatively pricey at 17.8. No increase in the dividend is forecast for either company, so GSK also retains its status as the superior yield pick.

Predictability and risk

Reading the range of City analysts’ earnings forecasts, as well as the consensus, it’s striking that the range around the GSK consensus is much tighter than the range around the AstraZeneca consensus. For the current year, the GSK high estimate is 8% above consensus, with the low estimate 7% below. In AstraZeneca’s case, the range is from +16% to -20%.

I think this tells us that GSK’s earnings are more predictable than its rival’s, and that AstraZeneca has higher risk of an earnings consensus miss, and a miss of greater magnitude — whether to the upside or the downside. That GSK’s earnings are more predictable makes sense, because unlike pureplay pharma AstraZeneca, it has a large consumer healthcare products business, with superior earnings visibility.

Bottom line

On balance, I see GSK’s valuation (and diversified business) as more attractive than AstraZeneca’s. Furthermore, due to its reasonable P/E and appealing dividend yield, I’d be happy to buy GSK today.

Conversely, I’m avoiding AstraZeneca at this time, on the view its P/E is just too elevated, particularly with the risk presented by the wide range of estimates around the earnings consensus. The inferior dividend yield is an added negative.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

A Lloyds share price of 80p by the end of summer? Here’s how it could happen

I'd see it as a mistake to try to make any firm Lloyds share price predictions. But that doesn't stop…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Top US dividend shares to consider in April

As the last remnants of winter slowly fade away, Mark Hartley is looking for promising dividend shares from across the…

Read more »

Investing Articles

Here’s the dividend forecast for M&G shares in 2025 and 2026

Roland Head looks at the latest dividend forecasts for FTSE 100 asset manager M&G. Is this 9% yield a safe…

Read more »

Retirement Articles

Putting £500 a month into a SIPP from the age of 40 could lead to over £500k by retirement

By putting money into a SIPP at 40 and investing properly, an investor could build significant savings by the time…

Read more »

Investing Articles

Are BAE Systems shares still a bargain near a 52-week high?

Charlie Carman evaluates where BAE Systems shares could go next as geopolitical turmoil drives global military expenditure to record levels.

Read more »

Girl buying groceries in the supermarket with her father.
Investing Articles

What on earth’s going on with the Unilever share price?

Andrew Mackie examines the reasons behind the lack of direction in the Unilever share price over the past few years.

Read more »

Investing Articles

Here’s the dividend forecast for Rolls-Royce shares up to 2028

Can analyst forecasts offer a useful insight into dividend shares? Stephen Wright take a look with one of the FTSE…

Read more »

Investing Articles

I think these shares could skyrocket if the US stock market enters a new bull run

The US stock market has dipped, and this has impacted some shares more than others. Dr James Fox highlights several…

Read more »